Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?

It's a tough act to follow. Few biotech companies have made more noise than Viking Therapeutics (VKTX 4.41%) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the industry. However, Viking's prominence and stock price soared thanks to excellent clinical progress. The biotech's shares are up by 154% since early January. Why Viking Therapeutics has been on fire Among this herd of drugmakers -- outside of Eli Lilly and Novo Nordisk -- Viking Therapeutics ha ...